Mark Sutherland

1.2k citations

39 papers · 943 indexed · h-index 19

Impact in

Immunology top 10%
- Toxin Mechanisms and Immunotoxins
Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism

Papers in ⓘ

Immunology and Allergy 4
- Cell Adhesion Molecules Research 4
Immunology 13
- Toxin Mechanisms and Immunotoxins 12

Co-authors: Hendrik Fuchs (13 shared papers)Christopher Bachran (11 shared papers)Iring Heisler (7 shared papers)Diana Bachran (6 shared papers)Laurence H. Patterson (14 shared papers)Steven D. Shnyder (13 shared papers)Matthias F. Melzig (4 shared papers)T Schewe (4 shared papers)
Journals: Cancer Research (4 papers)Cancers (2 papers)Journal of Controlled Release (2 papers)International Journal of Cancer (2 papers)FEBS Letters (2 papers)
Partner nations: United Kingdom Germany United States

In The Last Decade

Mark Sutherland

38 papers receiving 915 citations

Peers

Countries citing papers authored by Mark Sutherland

Since Specialization

Citations

This map shows the geographic impact of Mark Sutherland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sutherland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sutherland more than expected).

Fields of papers citing papers by Mark Sutherland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Sutherland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sutherland. The network helps show where Mark Sutherland may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Sutherland, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Sutherland Line = papers co-authored together Mark Sutherland links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Saponins in Tumor Therapy Mini-Reviews in Medicinal Chemistry ·Christopher Bachran, Silke Bachran, Mark Sutherland, Diana Bachran, Hendrik Fuchs	2008	91
2	A Colorimetric Assay for the Quantitation of Free Adenine Applied to Determine the Enzymatic Activity of Ribosome-Inactivating Proteins Analytical Biochemistry ·Iring Heisler, Jutta Keller, R Tauber, Mark Sutherland, Hendrik Fuchs	2002	89
3	Saponins as Tool for Improved Targeted Tumor Therapies Current Drug Targets ·Hendrik Fuchs, Diana Bachran, Hossein Panjideh, Nicole Schellmann, Alexander Weng, Matthias F. Melzig, Mark Sutherland, Christopher Bachran	2009	64
4	RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis Cancers ·Mark Sutherland, Andrew H. Gordon, Steven D. Shnyder, Laurence H. Patterson, Helen M. Sheldrake	2012	56
5	Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells Journal of Controlled Release ·Iring Heisler, Mark Sutherland, Christopher Bachran, Philipp Hebestreit, Anna Schnitger, Matthias F. Melzig, Hendrik Fuchs	2005	55
6	Pharmacological Inhibition of polysialyltransferase ST8SiaII Modulates Tumour Cell Migration PLoS ONE ·Yousef Al–Saraireh, Mark Sutherland, Bradley R. Springett, Friedrich Freiberger, Goreti Ribeiro Morais, Paul M. Loadman, Rachel J. Errington, Paul J. Smith, Minoru Fukuda, Rita Gerardy‐Schahn, Laurence H. Patterson, Steven D. Shnyder, Robert A. Falconer	2013	49
7	The Saponin-Mediated Enhanced Uptake of Targeted Saporin-Based Drugs is Strongly Dependent on the Saponin Structure Experimental Biology and Medicine ·Christopher Bachran, Mark Sutherland, Iring Heisler, Philipp Hebestreit, Matthias F. Melzig, Hendrik Fuchs	2006	47
8	Evidence for the presence of phospholipid hydroperoxide glutathione peroxidase in human platelets: implications for its involvement in the regulatory network of the 12-lipoxygenase pathway of arachidonic acid metabolism Biochemical Journal ·Mark Sutherland, Pattabhiraman Shankaranarayanan, T Schewe, Santosh Nigam	2000	42
9	A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins International Journal of Cancer ·Iring Heisler, Jutta Keller, R Tauber, Mark Sutherland, Hendrik Fuchs	2002	40
10	Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder Molecular Cancer Therapeutics ·Mark Sutherland, Jason H. Gill, Paul M. Loadman, Jonathan P. Laye, Helen M. Sheldrake, Nicola A. Illingworth, Mohammed N. Alandas, Patricia A. Cooper, Mark Searcey, Klaus Pors, Steven D. Shnyder, Laurence H. Patterson	2012	36
11	15‐Lipoxygenation of phospholipids may precede the sn‐2 cleavage by phospholipases A₂: reaction specificities of secretory and cytosolic phospholipases A₂ towards native and 15‐lipoxygenated arachidonoyl phospholipids FEBS Letters ·Pavlos Chaitidis, T Schewe, Mark Sutherland, Hartmut Kühn, Santosh Nigam	1998	36
12	A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice Journal of Controlled Release ·Hendrik Fuchs, Christopher Bachran, Tongyu Li, Iring Heisler, Horst Dürkop, Mark Sutherland	2006	34
13	Inhibition of Tumor Growth by Targeted Toxins in Mice is Dramatically Improved by Saponinum Album in a Synergistic Way Journal of Immunotherapy ·Christopher Bachran, Horst Dürkop, Mark Sutherland, Diana Bachran, Christian D. Muller, Alexander Weng, Matthias F. Melzig, Hendrik Fuchs	2009	33
14	Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity Chemical Communications ·Klaus Pors, Paul M. Loadman, Steven D. Shnyder, Mark Sutherland, Helen M. Sheldrake, Meritxell Guinó, Konstantinos Kiakos, John A. Hartley, Mark Searcey, Laurence H. Patterson	2011	30
15	Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity Journal of Medicinal Chemistry ·Helen M. Sheldrake, Sandra Travica, Inger Johansson, Paul M. Loadman, Mark Sutherland, Lina Elsalem, Nicola A. Illingworth, Alexander J. Cresswell, Tristan Reuillon, Steven D. Shnyder, Souren Mkrtchian, Mark Searcey, Magnus Ingelman‐Sundberg, Laurence H. Patterson, Klaus Pors	2013	29
16	Biological actions of the free acid of hepoxilin A3 on human neutrophils Biochemical Pharmacology ·Mark Sutherland, T Schewe, Santosh Nigam	2000	27
17	Hepoxilin signaling in intact human neutrophils: biphasic elevation of intracellular calcium by unesterified hepoxilin A₃ FEBS Letters ·Dénis Reynaud, Peter Demin, Mark Sutherland, Santosh Nigam, C.R. Pace-Asciak	1999	24
18	Matrix metalloproteinase 2 is a target of the RAN-GTP pathway and mediates migration, invasion and metastasis in human breast cancer Life Sciences ·Mohamed El‐Tanani, Angela Platt‐Higgins, Yin-Fai Lee, Arwa Omar Al Khatib, Yusuf A. Haggag, Mark Sutherland, Shudong Zhang, Alaa A. A. Aljabali, Vijay Mishra, Ángel Serrano‐Aroca, Murtaza M. Tambuwala, Philip S. Rudland	2022	21
19	Changes in vascular dynamics of the adult rat testis leading to transient accumulation of seminiferous tubule fluid after administration of a novel 5-hydroxytryptamine (5-HT) agonist Reproductive Toxicology ·Jacqui Piner, Mark Sutherland, M. Millar, Katie J. Turner, D.R. Newall, Richard M. Sharpe	2002	19
20	Improved preparation and detection of cytochrome P450 isoforms using MS methods PROTEOMICS ·Chris W. Sutton, Mark Sutherland, Steven D. Shnyder, Laurence H. Patterson	2009	18

About Mark Sutherland

Mark Sutherland is a scholar working on Immunology and Allergy, Immunology, Biotechnology, Pharmacology and Molecular Biology, having authored 39 papers that have together received 943 indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (12 papers), Cancer therapeutics and mechanisms (5 papers), Pharmacogenetics and Drug Metabolism (5 papers), Natural product bioactivities and synthesis (4 papers), Cell Adhesion Molecules Research (4 papers), Neuroblastoma Research and Treatments (4 papers), Transgenic Plants and Applications (4 papers) and Chemical Synthesis and Analysis (3 papers). The work is most often cited by research in Immunology (293 citations), Pharmacology (118 citations), Biotechnology (103 citations), Biochemistry (63 citations) and Molecular Biology (581 citations). Mark Sutherland has collaborated with scholars based in United Kingdom, Germany and United States. Frequent co-authors include Hendrik Fuchs, Christopher Bachran, Iring Heisler, Diana Bachran, Laurence H. Patterson, Steven D. Shnyder, Matthias F. Melzig, T Schewe, R Tauber and Santosh Nigam. Their work appears in journals such as Cancer Research, Cancers, Journal of Controlled Release, International Journal of Cancer and FEBS Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact